2a(2),3a(2)-Difluoro-4a(2)-hydroxy[1,1a(2)-biphenyl]-4-carboxylic acid | 189161-84-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2a(2),3a(2)-Difluoro-4a(2)-hydroxy[1,1a(2)-biphenyl]-4-carboxylic acid
• 英文别名: 4-(2,3-difluoro-4-hydroxyphenyl)benzoic acid
• CAS: 189161-84-0
• 化学式: C₁₃H₈F₂O₃
• 分子量: 250.2
• InChiKey: FZNGZBOTXBLXSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Analgesic and glucosamine compositions
  申请人：Temple University of the Commonwealth of Higher Education

  公开号：US20020058642A1

  公开（公告）日：2002-05-16

  This invention relates to a composition comprising a glucosamine material and an analgesic compound such as a nonsteroidal anti-inflammatory drug (NSAID) and/or an opioid analgesic and its use for treatment of pain in pharmaceutical or veterinary applications. When the components of the compositions are administered within certain ratios, the analgesic efficacy of the composition is super-additive (synergistic) relative to the analgesic efficacy of the analgesic compound alone.

  本发明涉及一种包含葡萄糖胺物质和镇痛化合物（如非甾体抗炎药（NSAID）和/或阿片类镇痛剂）的组合物及其在药物或兽医应用中用于治疗疼痛的用途。当组合物的成分在一定比例内给予时，相对于单独使用镇痛化合物，组合物的镇痛效果是超加性（协同作用的）。
• FATTY ACID ACYLATED SALICYLATES AND THEIR USES
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：US20160083336A1

  公开（公告）日：2016-03-24

  The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative.

  该发明涉及脂肪酸酰化水杨酸衍生物；包含有效量的脂肪酸酰化水杨酸衍生物的组合物；以及治疗或预防炎症性疾病的方法，其中包括给予有效量的脂肪酸酰化水杨酸衍生物的管理。
• Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
  申请人：——

  公开号：US20030000518A1

  公开（公告）日：2003-01-02

  The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an NSAID. In a method aspect of the present invention, an NSAID is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an NSAID, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an NSAID through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an NSAID; and, b) a device that forms an NSAID aerosol from the composition, for inhalation by the mammal.

  本发明涉及通过吸入途径输送非甾体抗炎药（NSAIDs）。具体而言，本发明涉及用于吸入治疗的含有非甾体抗炎药的气雾剂。在本发明的一个组合物方面，气雾剂包括含有至少 5%（按重量计）非甾体抗炎药的颗粒。在本发明方法的一个方面，通过吸入途径向哺乳动物提供非甾体抗炎药。该方法包括：a)加热组合物，其中组合物包含按重量计至少5%的非甾体抗炎药，以形成蒸气；b)使蒸气冷却，从而形成包含颗粒的凝结气溶胶，由哺乳动物吸入。在本发明的一个试剂盒方面，提供了一种通过吸入途径向哺乳动物递送非甾体抗炎药的试剂盒，该试剂盒包括：a) 一种组合物，按重量计包含至少 5% 的非甾体抗炎药；b) 一种装置，从组合物中形成非甾体抗炎药气溶胶，供哺乳动物吸入。
• ANALGESIC AND GLUCOSAMINE COMPOSITIONS
  申请人：Temple University of the Commonwealth System of Higher Education

  公开号：EP1328278A1

  公开（公告）日：2003-07-23
• EP1328278A4
  申请人：——

  公开号：EP1328278A4

  公开（公告）日：2004-06-16